arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Actinium Pharmaceuticals, Inc.

ATNM
$0.80 ▲ +0.03 (+3.71%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
82 Visible periods
23 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Actinium Pharmaceuticals, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $25.0M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -202.4%
FCF / Share $-0.19
Trailing P/E
Price / Book 10.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

82-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-5.52M
↑ +65.4%
FCF / Share Free cash flow per share
$-0.19
↑ +22.6%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -365.5% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.73x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 26 years · 82 quarters